Literature DB >> 7142993

Immunochemical studies of bovine and human choline-O-acetyltransferase using monoclonal antibodies.

A I Levey, D B Rye, B H Wainer.   

Abstract

Immunochemical properties of bovine and human choline acetyltransferase (ChAT, EC 2.3.1.6, acetyl-CoA:choline-O-acetyltransferase) were studied using six monoclonal antibodies (AB1, AB5, AB6, AB7, AB8, and AB9) reactive with the enzyme. All antibodies except AB1 bound specifically to two proteins of 68,000 and 70,000 MW on "Western" blots of sodium dodecyl sulfate-polyacrylamide gels containing human or bovine ChAT. The enzyme was specifically absorbed to immobilized antibody and could not be eluted by low pH and/or high salt concentrations although the enzyme retained activity on the immunoabsorbent. Pure bovine enzyme consisting of the same two proteins as seen in the Western blotting studies was eluted from immobilized AB1 in the presence of sodium dodecyl sulfate. Although active enzyme could not be eluted from immobilized antibodies by standard conditions, various combinations of free and immobilized antibodies were effective in competing off bound enzyme. Free antibody AB1 quantitatively eluted the active enzyme from immobilized AB1. The different capacities of the antibodies to elute enzyme from various immunoabsorbents reflect interesting properties of both the enzyme and the antibodies.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7142993     DOI: 10.1111/j.1471-4159.1982.tb07999.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  2 in total

Review 1.  Molecular biology and neurobiology of choline acetyltransferase.

Authors:  P M Salvaterra
Journal:  Mol Neurobiol       Date:  1987       Impact factor: 5.590

2.  Anti-human choline acetyltransferase fragments antigen binding (FAB)-sepharose chromatography for enzyme purification.

Authors:  J H Peng; P L McGeer; E G McGeer
Journal:  Neurochem Res       Date:  1983-11       Impact factor: 3.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.